Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
暂无分享,去创建一个
M. Siedner | T. Vyas | J. Vyas | J. Boucau | M. Choudhary | A. Barczak | C. Marino | R. Uddin | Yumeko Kawano | M. Y. Liew | Mamadou Barry | Dessie Tien | Shruti Sagar | Tin Phan | Alan S. Perelson | Yijia Li | Gregory E. Edelstein | Jeffrey A. Sparks | Sarah P. Hammond | Jacob E. Lemieux | Jonathan Z. Li | Ruy M. Ribeiro | Karry Su | Zahra Reynolds | Zachary S Wallace